Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAIReD (Pilot of Allogenic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma.

Next Previous
Search
Trial Profile

PAIReD (Pilot of Allogenic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab; Carmustine; Ciclosporin; Ciclosporin; Cytarabine; Etoposide; Lomustine; Melphalan; T cell replacement therapy
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Acronyms PAIReD

    • Most Recent Events

    • 05 Dec 2013 Planned end date changed from 31 Jul 2014 to 31 Mar 2014 as reported by United Kingdom Clinical Research Network record.
    • 23 Nov 2013 Accrual to date is 90% according to United Kingdom Clinical Research Network.
    • 16 Oct 2013 Accrual to date is 78% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top